Amparo Tatiane Roquete, Sousa Lucas Resende Dutra, Xavier Viviane Flores, Seibert Janaína Brandão, Paiva Débora Luiza, da Silva Débora Dos Santos, Teixeira Luiz Fernando de Medeiros, Dos Santos Orlando David Henrique, Vieira Paula Melo de Abreu, de Souza Gustavo Henrique Bianco, Brandão Geraldo Célio
Department of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, Brazil.
Laboratory of Pathology and Microbial Control, University of São Paulo (USP-ESALQ), Piracicaba 13418-900, Brazil.
Pharmaceutics. 2024 May 23;16(6):700. doi: 10.3390/pharmaceutics16060700.
The treatment of skin and soft tissue infections (SSTIs) can be challenging due to bacterial resistance, particularly from strains like MRSA and biofilm formation. However, combining conventional antibiotics with natural products shows promise in treating SSTIs. The objective of this study is to develop a nanoemulsion-based hydrogel containing extract and mupirocin and evaluate its potential for the treatment of SSTIs. The nanoemulsion was obtained by phase inversion and subsequently characterized. The antibacterial activity was evaluated in vitro against MRSA, including the synergism of the combination, changes in membrane permeability using flow cytometry, and the anti-biofilm effect. In addition, the irritative potential was evaluated by the HET-CAM assay. The combination exhibited synergistic antibacterial activity against and MRSA due to the extract enhancing membrane permeability. The hydrogel demonstrated suitable physicochemical properties, inhibited biofilm formation, and exhibited low irritation. The formulation was nanometric (176.0 ± 1.656 nm) and monodisperse (polydispersity index 0.286 ± 0.011). It exhibited a controlled release profile at 48 h and high encapsulation efficacy (94.29 ± 4.54% for quercitrin and 94.20 ± 5.44% for mupirocin). Therefore, these findings suggest that the hydrogel developed could be a safe and effective option for treating SSTIs.
由于细菌耐药性,尤其是耐甲氧西林金黄色葡萄球菌(MRSA)等菌株以及生物膜形成,皮肤和软组织感染(SSTIs)的治疗可能具有挑战性。然而,将传统抗生素与天然产物联合使用在治疗SSTIs方面显示出前景。本研究的目的是开发一种含有提取物和莫匹罗星的纳米乳液基水凝胶,并评估其治疗SSTIs的潜力。通过相转化获得纳米乳液并随后进行表征。体外评估了其对MRSA的抗菌活性,包括联合用药的协同作用、使用流式细胞术检测膜通透性的变化以及抗生物膜效果。此外,通过鸡胚绒毛尿囊膜(HET-CAM)试验评估了其刺激潜力。由于提取物增强了膜通透性,该联合用药对[未提及的细菌]和MRSA表现出协同抗菌活性。该水凝胶表现出合适的物理化学性质,抑制生物膜形成,且刺激性低。该制剂为纳米级(176.0±1.656 nm)且单分散(多分散指数0.286±0.011)。它在48小时表现出控释特性且具有高包封率(槲皮苷为94.29±4.54%,莫匹罗星为94.20±5.44%)。因此,这些发现表明所开发的水凝胶可能是治疗SSTIs的一种安全有效的选择。